Michael Ezrokhi

541 total citations
22 papers, 422 citations indexed

About

Michael Ezrokhi is a scholar working on Physiology, Endocrinology, Diabetes and Metabolism and Endocrine and Autonomic Systems. According to data from OpenAlex, Michael Ezrokhi has authored 22 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Physiology, 11 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Endocrine and Autonomic Systems. Recurrent topics in Michael Ezrokhi's work include Diet and metabolism studies (11 papers), Circadian rhythm and melatonin (6 papers) and Adipose Tissue and Metabolism (6 papers). Michael Ezrokhi is often cited by papers focused on Diet and metabolism studies (11 papers), Circadian rhythm and melatonin (6 papers) and Adipose Tissue and Metabolism (6 papers). Michael Ezrokhi collaborates with scholars based in United States and Canada. Michael Ezrokhi's co-authors include Anthony H. Cincotta, Richard E. Scranton, Dean Rutty, J. Michael Gaziano, Zhulin Ma, Christopher M. O’Connor, Shuqin Luo, Bindu Chamarthi, Aaron I. Vinik and Tsung‐Huang Tsai and has published in prestigious journals such as Diabetes Care, Diabetes and International Journal of Molecular Sciences.

In The Last Decade

Michael Ezrokhi

21 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Ezrokhi United States	11	250	161	100	99	84	22	422
Silvia Genghini Italy	8	229 0.9×	133 0.8×	30 0.3×	66 0.7×	138 1.6×	8	529
Miriam Lettieri United Kingdom	4	122 0.5×	90 0.6×	58 0.6×	92 0.9×	69 0.8×	5	316
Mohamad Mokadem United States	7	101 0.4×	229 1.4×	172 1.7×	69 0.7×	142 1.7×	26	409
Ana B. Fernandes Portugal	7	155 0.6×	87 0.5×	217 2.2×	103 1.0×	85 1.0×	21	417
Stina Johansson Sweden	8	64 0.3×	100 0.6×	97 1.0×	91 0.9×	58 0.7×	9	360
Kirsten Lykkegaard Denmark	10	105 0.4×	120 0.7×	72 0.7×	128 1.3×	97 1.2×	14	370
Simone van de Sande‐Lee Brazil	9	90 0.4×	151 0.9×	67 0.7×	26 0.3×	99 1.2×	28	331
Ayhan Bozkurt Türkiye	5	260 1.0×	118 0.7×	166 1.7×	67 0.7×	139 1.7×	7	448
Farhana Naznin Japan	7	81 0.3×	139 0.9×	65 0.7×	81 0.8×	170 2.0×	7	354
Adam Horblitt United States	8	138 0.6×	83 0.5×	186 1.9×	100 1.0×	158 1.9×	11	354

Countries citing papers authored by Michael Ezrokhi

Since Specialization

Citations

This map shows the geographic impact of Michael Ezrokhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Ezrokhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Ezrokhi more than expected).

Fields of papers citing papers by Michael Ezrokhi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Ezrokhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Ezrokhi. The network helps show where Michael Ezrokhi may publish in the future.

Co-authorship network of co-authors of Michael Ezrokhi

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Ezrokhi. A scholar is included among the top collaborators of Michael Ezrokhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Ezrokhi. Michael Ezrokhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chamarthi, Bindu, Michael Ezrokhi, Carl R. Stoelzel, & Anthony H. Cincotta. (2025). Circadian-timed Cycloset Therapy Reduces Cardiovascular Event Rate in Type 2 Diabetes (T2DM) Subjects with Clinical Features Suggestive of Elevated Sympathetic Nervous System Activity – Pilot Study Results. Metabolism. 168. 156224–156224.

Zhang, Yahong, Tsung‐Huang Tsai, Michael Ezrokhi, Carl R. Stoelzel, & Anthony H. Cincotta. (2023). Tyrosine Hydroxylase Knockdown at the Hypothalamic Supramammillary Nucleus Area Induces Obesity and Glucose Intolerance. Neuroendocrinology. 114(5). 483–510. 1 indexed citations

Cincotta, Anthony H., Eugênio Cersósimo, Michael Ezrokhi, et al.. (2022). Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects. International Journal of Molecular Sciences. 23(16). 8851–8851. 8 indexed citations

Zhang, Yahong, Carl R. Stoelzel, Michael Ezrokhi, Tsung‐Huang Tsai, & Anthony H. Cincotta. (2021). Activation State of the Supramammillary Nucleus Regulates Body Composition and Peripheral Fuel Metabolism. Neuroscience. 466. 125–147. 3 indexed citations

Luo, Shuqin, et al.. (2021). Experimental dopaminergic neuron lesion at the area of the biological clock pacemaker, suprachiasmatic nuclei (SCN) induces metabolic syndrome in rats. Diabetology & Metabolic Syndrome. 13(1). 11–11. 16 indexed citations

Ezrokhi, Michael, Yahong Zhang, Shuqin Luo, & Anthony H. Cincotta. (2021). Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet. International Journal of Molecular Sciences. 22(11). 6142–6142. 8 indexed citations

Chamarthi, Bindu, Michael Ezrokhi, & Anthony H. Cincotta. (2020). 1083-P: Bromocriptine-QR (BQR) Reduces Hypertriglyceridemia (HTG) in Hypertensive Type 2 Diabetes (T2D) Subjects. Diabetes. 69(Supplement_1). 1 indexed citations

Moore, Mary Courtney, Marta S. Smith, Larry L. Swift, et al.. (2020). Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model. American Journal of Physiology-Endocrinology and Metabolism. 319(1). E133–E145. 2 indexed citations

Zhang, Yahong, et al.. (2020). 1823-P: Bromocriptine (BC) Normalizes Elevated Expression of Liver Genes Involved in Fatty Acid Oxidation, Lipogenesis, Inflammation, and Endoplasmic Reticulum (ER) Stress and Glucose Intolerance of High-Fat/Sucrose Diet-Fed Rats. Diabetes. 69(Supplement_1). 1 indexed citations

10.

Ezrokhi, Michael, et al.. (2019). 1793-P: Dopamine D1 plus D2 Receptor Coactivation Ameliorates Metabolic Syndrome (MS) and Nonalcoholic Fatty Liver Disease (NAFLD) in Mice. Diabetes. 68(Supplement_1). 1 indexed citations

11.

Luo, Saiyu, et al.. (2017). Circadian peak dopaminergic activity response at the biological clock pacemaker (suprachiasmatic nucleus) area mediates the metabolic responsiveness to a high‐fat diet. Journal of Neuroendocrinology. 30(1). 24 indexed citations

12.

Chamarthi, Bindu, Michael Ezrokhi, Dean Rutty, & Anthony H. Cincotta. (2016). Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin. Postgraduate Medicine. 128(8). 761–769. 15 indexed citations

13.

Ezrokhi, Michael, et al.. (2014). Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetology & Metabolic Syndrome. 6(1). 104–104. 32 indexed citations

14.

Vinik, Aaron I., Anthony H. Cincotta, Richard E. Scranton, et al.. (2012). Effect of Bromocriptine-Qr On Glycemic Control in Subjects with Uncontrolled Hyperglycemia On One or Two Oral Anti-Diabetes Agents. Endocrine Practice. 18(6). 931–943. 28 indexed citations

15.

Ezrokhi, Michael, et al.. (2012). Weighted Effects of Bromocriptine Treatment on Glucose Homeostasis during Hyperglycemic versus Euglycemic Clamp Conditions in Insulin Resistant Hamsters: Bromocriptine as a Unique Postprandial Insulin Sensitizer. Journal of Diabetes & Metabolism. S2(1). 14 indexed citations

16.

Flórez, Hermes, Richard E. Scranton, Wildon Farwell, Ralph A. DeFronzo, & Michael Ezrokhi. (2011). Randomized Clinical Trial Assessing the Efficacy and Safety of Bromocriptine-QR when Added to Ongoing Thiazolidinedione Therapy in Patients with Type 2 Diabetes Mellitus. Journal of Diabetes & Metabolism. 2(5). 20 indexed citations

17.

Gaziano, J. Michael, Anthony H. Cincotta, Christopher M. O’Connor, et al.. (2010). Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes. Diabetes Care. 33(7). 1503–1508. 152 indexed citations

18.

Cincotta, Anthony H., J. Michael Gaziano, Michael Ezrokhi, & Richard E. Scranton. (2008). Cycloset (Quick-Release Bromocriptine Mesylate), a Novel Centrally Acting Treatment for Type 2 Diabetes. Canadian Journal of Diabetes. 32(4). 323–323. 6 indexed citations

19.

Scranton, Richard E., Wildon Farwell, Michael Ezrokhi, J. Michael Gaziano, & Anthony H. Cincotta. (2008). Quick Release Bromocriptine (Cycloset™) Improves Glycemic Control in Patients with Diabetes Failing Metformin/Sulfonylurea Combination Therapy. Canadian Journal of Diabetes. 32(4). 324–324. 2 indexed citations

20.

Scranton, Richard E., J. Michael Gaziano, Dean Rutty, Michael Ezrokhi, & Anthony H. Cincotta. (2007). A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset™ or placebo. BMC Endocrine Disorders. 7(1). 3–3. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact